Literature DB >> 10762457

Chlamydia pneumoniae in atherosclerosis.

P Saikku1.   

Abstract

Chlamydia pneumoniae is currently the infectious agent most often associated with the inflammation found in atherosclerosis. The seroepidemiological association and the actual presence of pathogen in lesions has been confirmed in numerous studies, in which technical difficulties seem to be the only limitation. Besides animal experiments and intervention trials, we need information of possible pathogenic mechanisms. Recently, several studies have suggested mechanisms by which C. pneumoniae infection could participate in the development of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762457     DOI: 10.1046/j.1365-2796.2000.00659.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  10 in total

1.  Characterization of antiapoptotic activities of Chlamydia pneumoniae in human cells.

Authors:  S F Fischer; C Schwarz; J Vier; G Häcker
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

2.  Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions.

Authors:  B Rafferty; D Jönsson; S Kalachikov; R T Demmer; R Nowygrod; M S V Elkind; H Bush; E Kozarov
Journal:  J Intern Med       Date:  2011-04-11       Impact factor: 8.989

3.  Single-run, parallel detection of DNA from three pneumonia-producing bacteria by real-time polymerase chain reaction.

Authors:  Reinhard B Raggam; Eva Leitner; Jörg Berg; Gerhard Mühlbauer; Egon Marth; Harald H Kessler
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

4.  Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages.

Authors:  Hiroyuki Yamaguchi; Shusaku Haranaga; Ray Widen; Herman Friedman; Yoshimasa Yamamoto
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

5.  Identification and characterization of Chlamydia pneumoniae-specific proteins that activate tumor necrosis factor alpha production in RAW 264.7 murine macrophages.

Authors:  Shinn-Jong Jiang; Cho-Chou Kuo; Mark W Berry; Amy W Lee; Lee Ann Campbell
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

Review 6.  Therapeutic targeting of NOD1 receptors.

Authors:  L Moreno; T Gatheral
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

7.  Novel Chlamydia pneumoniae vaccine candidates confirmed by Th1-enhanced genetic immunization.

Authors:  Yihang Li; Sudhir K Ahluwalia; Alexandre Borovkov; Andrey Loskutov; Chengming Wang; Dongya Gao; Anil Poudel; Kathryn F Sykes; Bernhard Kaltenboeck
Journal:  Vaccine       Date:  2009-12-02       Impact factor: 3.641

8.  The Chlamydia outer membrane protein OmcB is required for adhesion and exhibits biovar-specific differences in glycosaminoglycan binding.

Authors:  Katja Moelleken; Johannes H Hegemann
Journal:  Mol Microbiol       Date:  2007-12-11       Impact factor: 3.501

9.  Determination of PCR efficiency in chelex-100 purified clinical samples and comparison of real-time quantitative PCR and conventional PCR for detection of Chlamydia pneumoniae.

Authors:  Tina Mygind; Svend Birkelund; Niels H Birkebaek; Lars Østergaard; Jørgen Skov Jensen; Gunna Christiansen
Journal:  BMC Microbiol       Date:  2002-07-09       Impact factor: 3.605

Review 10.  Role of Nucleotide-binding and Oligomerization Domain 2 Protein (NOD2) in the Development of Atherosclerosis.

Authors:  Ha-Jeong Kim
Journal:  Korean J Physiol Pharmacol       Date:  2015-10-16       Impact factor: 2.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.